PROCEPT BioRobotics Corporation filings document the public-company disclosures of a Nasdaq-listed surgical robotics business focused on urology. Recent Form 8-K reports furnish quarterly financial results, revenue and operating commentary, investor presentation materials, and updates tied to the company’s AQUABEAM and HYDROS Robotic Systems, Aquablation therapy, and related product and clinical programs.
Proxy and governance filings cover board composition, committee assignments, director independence, executive compensation, equity awards, and severance or change-of-control arrangements. The filings also identify PRCT common stock registered under Section 12(b) and traded on The Nasdaq Global Market.
PROCEPT BioRobotics Corp (PRCT) reported third-quarter revenue of $98.3 million, up 18% from a year earlier, and nine-month revenue of $275.9 million, up 19%. Handpieces and other consumables and service revenue increased; U.S. revenue was $85.8 million in the quarter. Gross margin was 66%, compared with 65%, and the company attributed the increase primarily to $3.2 million of tariff refunds.
Net loss was $26.5 million for the quarter versus $21.4 million, and $85.0 million for nine months versus $65.7 million. Nine-month operating cash use was $66.4 million, compared with $38.7 million. As of September 30, 2026, cash and cash equivalents were $218.4 million and term-loan principal outstanding was $52.0 million. The loan maturity was extended by 12 months to October 1, 2028; the company reported compliance with all debt covenants. Management currently believes existing cash and anticipated revenue will fund operations through at least 12 months from the financial statements’ issuance date. The company had 1,095 robotic systems installed globally, including 858 in the United States.
PROCEPT BioRobotics reported third-quarter 2026 revenue of $98.3 million, up 18% from a year earlier. U.S. revenue was $85.8 million, up 16%; U.S. handpiece and consumables revenue was $53.9 million, up 21%, while U.S. system revenue was $24.7 million, flat. International revenue rose 32% to $12.5 million. U.S. procedures exceeded 13,400, up approximately 22%, and gross margin was 66%, compared with 65%.
Operating expenses were $92.5 million, compared with $77.2 million, reflecting investment in people, product development, clinical studies, and sales and marketing. Net loss was $26.5 million, versus $21.4 million, and adjusted EBITDA loss, a non-GAAP measure, was $9.8 million versus $7.4 million. Cash, cash equivalents and restricted cash totaled approximately $221.4 million as of September 30, 2026.
The company reaffirmed 2026 revenue guidance of $390 million to $410 million, representing 27% to 33% growth, and U.S. procedure guidance of 54,000 to 56,000, representing 25% to 29% growth. It reiterated gross margin of approximately 65% and adjusted EBITDA loss guidance of $35 million to $30 million.
PROCEPT BioRobotics Corp (PRCT) is the issuer whose common stock is covered by Vanguard Capital Management’s amended ownership report. Vanguard Capital Management reported beneficial ownership of 2,845,781 shares, or 4.96% of the class. It reported sole voting power over 433,130 shares and sole dispositive power over 2,845,781 shares, with zero shared voting or dispositive power. The reported securities include holdings attributed to Vanguard Capital Management LLC and named affiliates or business divisions, including Vanguard funds and client accounts over which those entities exercise voting and/or dispositive power.
PROCEPT BioRobotics Corp director Michael Mack received 7,727 restricted stock units (RSUs) and a stock option covering 12,191 shares of common stock on October 2, 2026. Each RSU represents a contingent right to receive one share. The option has a $17.16 exercise price per share and expires October 1, 2036.
PROCEPT BioRobotics Corp (PRCT) approved expanding its board from nine to ten members and appointed Dr. Michael Mack as an independent Class II director, effective immediately. His initial term expires at the 2029 annual meeting and continues until his successor is elected and qualified, or until his earlier death, resignation or removal. Dr. Mack is a cardiac surgeon who has practiced in Dallas since 1982 and has more than 1,100 peer-reviewed publications. He will be compensated consistently with the company’s other non-employee directors and will enter into its standard director and officer indemnification and advancement agreement. The company stated that there are no arrangements or understandings with other persons connected to the appointment and no transactions involving Dr. Mack requiring disclosure under related-party transaction rules.
PROCEPT BioRobotics Corp. (PRCT) entered into a third amendment to its Loan and Security Agreement with Canadian Imperial Bank of Commerce, extending the term loan maturity date by 12 months, from October 1, 2027 to October 1, 2028. The agreement otherwise remains in full force and effect and continues to be subject to the same affirmative and negative covenants previously disclosed.
PROCEPT BioRobotics Corp (PRCT) executive Alaleh Nouri, EVP, CLO and Corporate Secretary, reported a small sale of common stock primarily for tax purposes. On September 9, 2026, 297 shares were sold at $20.953 per share under the company’s sell-to-cover process tied to RSU vesting. Following this tax-withholding sale, Nouri directly holds 127,737 shares of PROCEPT BioRobotics common stock.
PROCEPT BioRobotics Corp (PRCT) reported that executive vice president and chief technology officer Barry L. Templin sold 373 shares of common stock on September 9, 2026 at $20.95 per share. According to the company, the sale was made under its sell-to-cover process to satisfy tax withholding on restricted stock units that vested on September 5, 2026. Following this tax-related sale, Templin directly holds 94,826 shares of PROCEPT BioRobotics common stock.
PROCEPT BioRobotics Corp (PRCT) reported an insider transaction by Kevin Waters, EVP and CFO. On September 9, 2026, he sold 373 shares of common stock at $20.953 per share in an open-market or private transaction pursuant to the company’s sell-to-cover tax withholding process, and continued to hold 180,355 shares directly afterward.